Language
European Parliament
Every sitting is free to watch on Polyfact, live and on replay, no account needed.
What is said in the sittings, update by update, the latest first. Each update opens the video at the second it was said.
Committee on Public Health Ordinary meeting
The Chair summarizes remaining gaps in pediatric cancer policy and funding, then formally closes that agenda item and opens a new ‘Excellence in Health Science’ exchange on TechBio and AI in drug discovery, introducing the next speaker and format.
In this chapter
Committee on Public Health Ordinary meeting
Scientific and NGO experts outline failures of current orphan and pharma frameworks, argue for specific SPC extensions and new EU‑level funding and procurement tools, and debate with MEPs on rare disease law, EMA and HTA procedures, reimbursement delays and the design of a non‑profit academia–industry vehicle.
In this chapter
Committee on Public Health Ordinary meeting
MEPs react to the testimonies by calling for an EU pediatric cancer pathway, stronger funding and health competences, and raise detailed questions on data, pharma obligations and existing EU instruments before the Chair closes the first segment and moves to the expert panel.
In this chapter
Committee on Public Health Ordinary meeting
The Chair opens the SANT meeting on childhood cancer, President Metsola provides the political framing and EU commitments, and survivor and parent‑economist testimonies expose treatment inequalities, market failures and the case for an EU‑level pediatric oncology pathway.
In this chapter
Committee on Public Health Ordinary meeting
Members question the Commission on legal bases, information tools and sustainable EU funding as the Commission explains the interaction between the directive and social security coordination, limits on prior authorisation, digital simplification and ERN support, before the rapporteur issues a political funding call and the Chair sets amendment deadlines and closes the sitting.
In this chapter
Committee on Public Health Ordinary meeting
Rapporteur Georgiou presents draft report priorities on updating the directive, tackling prohibitive out-of-pocket costs and securing higher EU funding, while political groups set out their positions on access, ERNs, digital health alignment, equity and patient protection against unsafe treatments abroad.
In this chapter
Committee on Public Health Ordinary meeting
Political and expert debate on whether obstacles stem mainly from national implementation or the directive itself, treatment of upfront payments and prior authorisation, potential upgrading of the directive and strengthening of ERNs, and options for new EU-level funding or solidarity instruments linked to biotech and pharmaceutical contributions.
In this chapter
Committee on Public Health Ordinary meeting
Presentation of the European Added Value Assessment on cross-border healthcare, detailing the three‑pillar roadmap on patient access, ERNs, telemedicine and the European Health Data Space, followed by rapporteur and shadow rapporteur reactions on persistent barriers, legislative versus implementation gaps, and needs of vulnerable patient groups.
In this chapter
Committee on Public Health Ordinary meeting
Formal opening of the committee meeting, adoption of the agenda, coordinators’ announcements and political framing of 2027 health budget priorities, followed by the detailed voting sequence on the 2027 EU general budget health lines and immediate procedural follow-up.
MEPs question the experts on mortality, inequalities, sector priorities, agriculture and regulatory ambition; experts reply on integrating health authorities, strengthening agricultural and heating rules, and targeting vulnerable groups, before final remarks on farming efforts and formal closure of the session.
In this chapter
Chairs introduce the Policy Department study on PM2.5 as a public health priority, and invited experts present scientific evidence on health impacts, trends, regulatory drivers, major remaining emission gaps and recommended upgrades to EU air‑quality and sectoral policies.
In this chapter
Co‑rapporteurs and shadows present and debate amendments on organ processing and genetically modified microorganisms, contrasting innovation goals with strong safeguards on ethics, non‑commercial organ use, risk‑based authorisation, data protection, delegated powers and traceability, followed by Commission defence of the proposals and procedural next steps.
In this chapter
Chairs open the joint SANT–ENVI meeting, resolve technical and procedural issues, adopt the agenda and minutes, and outline the joint procedure for handling the biotech directives within the European Biotech Act framework.
In this chapter
Committee on Public Health Ordinary meeting
Combined Q&A rounds where MEPs question EMA on the Critical Medicines Act, shortages tools, transparency and pricing context, environmental and wastewater rules, support for ATMPs and academic developers, and the Agency’s evolving MDR/IVDR mandate, with Cooke detailing current instruments, legal limits and planned pilots. This segment concentrates the main political, regulatory and implementation issues around medicine availability, innovation pathways and the EMA’s future responsibilities.
In this chapter
Committee on Public Health Ordinary meeting
Emer Cooke’s closing‑mandate intervention outlines EMA’s key outputs for 2025, explains how the revised pharmaceutical, health data and medical device frameworks will operate in practice, and draws regulatory and governance lessons from COVID‑19 and other recent health crises.
Committee on Public Health Ordinary meeting
Closing exchanges on MDR/IVDR safety, inspections and the Commission’s risk‑based approach lead into the formal conclusion of this legislative item and the Chair’s opening of the next agenda point on EMA’s 2023 annual report, including clarification of speaking order and amendment deadlines.
In this chapter
Committee on Public Health Ordinary meeting
The chair and rapporteur introduce the MDR/IVDR revision mandate and six‑pillar reform approach, followed by political group reactions on safety, innovation, AI and industrial policy, and the presentation of IMCO and BUDG opinions on AI scope, oversight, financing and resources, before individual MEPs highlight practical concerns on implementation and alignment with related EU rules.
In this chapter
Committee on Public Health Ordinary meeting
The rapporteur outlines priorities for the 2027 EU health budget opinion, followed by political group reactions opposing EU4Health cuts and a broader debate on overall funding levels, spending efficiency and the amendment timetable.
In this chapter
Committee on Public Health Ordinary meeting
Committee confirms the inter‑institutional agreement on the Critical Medicines Act, with the rapporteur detailing key provisions on security of supply and strategic autonomy before the formal vote approving the deal.
Committee on Public Health Ordinary meeting
A second round of MEPs links competitiveness and climate costs to health financing, raises digital health, AI, clinical trials, gender bias and the cancer ‘right to be forgotten’, followed by the Minister detailing Ireland’s stance on the EHDS, innovation, pricing, manufacturing, HTA and reducing inequalities.
In this chapter
Committee on Public Health Ordinary meeting
The Chair introduces the Irish Council Presidency’s health mandate, then MEPs open with questions on safeguarding the EU health budget, shaping the Biotech Act and pharma reform around affordability and access, and addressing AMR, One Health, workforce gaps and health inequalities.
In this chapter
Committee on Public Health Ordinary meeting
The Chair opens the agenda item on youth mental health and healthy behaviours, the Triple P expert presents parenting‑focused prevention and related policy implications, followed by MEPs’ questions and remarks on scaling parenting support, regulating digital risks and embedding youth mental health in EU frameworks.
In this chapter
Committee on Public Health Ordinary meeting
Presentation of the EPRS ‘cost of non-Europe’ study on youth mental health in the digital era, detailing methodology, prevalence, inequalities, digital risk factors and economic burden, followed by MEPs’ questions and experts’ replies on drivers of ill‑health, COVID and digital harms, EU competences, best practices and priority EU-level policy interventions.
In this chapter
Committee on Public Health Ordinary meeting
Report on the SANT delegation’s mission to the 79th World Health Assembly focusing on WHO reform, financing after US withdrawal, the Pandemic Agreement and PABS, and the EU’s political and financial stance, followed by debate on WHO independence, private funding and alleged foundation influence before closing the mission report.
Committee on Public Health Ordinary meeting
Opening of the SANT meeting, adoption of the agenda and explanation of the committee’s mission to Washington and Pittsburgh, followed by detailed feedback on US health stakeholders, ‘America First’ health policy, global health implications, and risks for EU health systems and access to medicines.
In this chapter
Committee on Public Health Ordinary meeting Joint meeting Committee on Industry, Research and Energy
The Commission justifies its proposal, insisting on unchanged safety and ethics, explains the conditional 12‑month SPC incentive and its links with wider pharmaceutical files, while the co‑rapporteurs rebut criticism, restate the Act’s key pillars, outline compromise work and the Chair announces the amendment deadline before closing.
In this chapter
Committee on Public Health Ordinary meeting Joint meeting Committee on Industry, Research and Energy
The JURI rapporteur and catch‑the‑eye MEPs debate ethical and legal safeguards for AI in healthcare, oppose or defend SPC extensions, call for stronger harmonisation of trials, raise concerns about reliance on non‑EU data, and highlight centres of excellence, skills and geographic balance of biotech activities.
In this chapter
Committee on Public Health Ordinary meeting Joint meeting Committee on Industry, Research and Energy
Shadows from EPP, S&D, ID, ECR, Renew, Greens and ENS set out their positions on biotech sovereignty, clinical trial timelines and governance, data protection, IP and SPC extensions, strategic project criteria, ethical safeguards and the balance between industrial incentives, biosimilars and affordability.
In this chapter
Committee on Public Health Ordinary meeting Joint meeting Committee on Industry, Research and Energy
The Chair opens the joint SANT–ITRE meeting, sets out procedure and context, and the co‑rapporteurs present their strategic vision for the European Biotech Act, focusing on competitiveness, clinical trials reform, data and AI use, EMA’s role and financing tools such as a scale‑up fund.
In this chapter
Committee on Public Health Ordinary meeting
The Chair summarises the main takeaways on AI as a support tool rather than a replacement for health professionals, highlights both opportunities and risks, thanks the experts, and announces the date of the next SANT meeting before closing the session.
The search covers the sittings held more than two weeks ago. A Polyfact subscription searches every sitting as soon as it is transcribed.
European Parliament broadcasts the sittings of the Committee on Public Health (SANT). Polyfact shows each one live, keeps it as a replay with its transcript and links its key moments to the second they were said.
47 sittings on Polyfact since 14 May 2025
Polyfact records and transcribes the sittings and committee hearings of European Union's parliaments. A speaker is named only once their identity is confirmed, by the official record or by a person; automatic guesses are left out.
On Polyfact, free and without an account: a sitting on air is marked live in the schedule above, and each sitting stays available as a replay.
Yes. Watching the sittings on Polyfact is free and needs no account. A Polyfact subscription, which you can try for free, adds the full transcripts as soon as they are ready, search across every sitting and alerts on your topics.
On each sitting's page on Polyfact, speaker by speaker, with its key moments one click from the second they were said. The search on this page covers the sittings held more than two weeks ago.
With a Polyfact plan you read every sitting as soon as it is transcribed, ask questions to the video assistant and get an alert as soon as your topics come up.
14-day free trial. A card is required, nothing is charged for 14 days, and you can cancel anytime.
Updated
